Aeterna Zentaris Inc. Share Price

Equities

AEZS

CA0079756007

Biotechnology & Medical Research

Market Closed - Toronto S.E. 18:37:10 17/07/2024 BST 5-day change 1st Jan Change
8.22 CAD -0.72% Intraday chart for Aeterna Zentaris Inc. -12.92% -20.04%

Financials

Sales 2022 5.64M 7.71M 434M Sales 2023 4.5M 6.15M 346M Capitalization 9.41M 12.87M 724M
Net income 2022 -22M -30.08M -1.69B Net income 2023 -16M -21.88M -1.23B EV / Sales 2022 -6.21 x
Net cash position 2022 50.43M 68.96M 3.88B Net cash position 2023 33.74M 46.13M 2.6B EV / Sales 2023 -5.41 x
P/E ratio 2022
-0.68 x
P/E ratio 2023
-0.57 x
Employees 12
Yield 2022 *
-
Yield 2023
-
Free-Float 98.41%
More Fundamentals * Assessed data
Dynamic Chart
Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director CI
Mannatech Names James Clavijo Finance Chief MT
Aeterna Zentaris Inc. Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency CI
Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly MT
Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction. CI
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger MT
Aeterna Zentaris Finalizes Some Details for Ceapro Merger MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro MT
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden MT
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Powell Awaited -2- DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency MT
More news

Latest transcript on Aeterna Zentaris Inc.

1 day-0.72%
1 week-12.92%
Current month+35.42%
1 month+0.24%
3 months-25.54%
6 months-20.96%
Current year-20.04%
More quotes
1 week
8.02
Extreme 8.02
8.87
1 month
5.40
Extreme 5.4
10.24
Current year
5.40
Extreme 5.4
15.13
1 year
5.40
Extreme 5.4
16.92
3 years
5.40
Extreme 5.4
124.00
5 years
5.40
Extreme 5.4
463.00
10 years
5.40
Extreme 5.4
16 800.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 31/12/98
Director of Finance/CFO - 23/01/22
Chief Administrative Officer - 30/09/15
Members of the board TitleAgeSince
Chief Executive Officer 70 31/12/19
Director/Board Member 62 14/05/20
Director/Board Member - 04/05/21
More insiders
Date Price Change Volume
17/07/24 8.22 -0.72% 557
16/07/24 8.28 -1.19% 100
15/07/24 8.38 -2.90% 1,058
12/07/24 8.63 -3.25% 3,803
11/07/24 8.92 -5.51% 1,000

Delayed Quote Toronto S.E., July 17, 2024 at 06:37 pm

More quotes
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.
More about the company